MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Calcium"

  • 2018 International Congress

    A Phase 2 Efficacy Study of CX-8998, a Potent and Selective T-Type Calcium (Cav3) Modulator in Parkinson’s disease Tremor (PDT) Patients: Design and Dose-Selection Rationale

    S. Papapetropoulos, M. Lee, S. Boyer, M. Versavel (Cambridge, MA, USA)

    Objective: The objective of this study is to access the efficacy of CX-8998 using the MDS-UPDRS Tremor Score (MDS-UPDRS-TS) and a digital biomarker platform, while…
  • 2018 International Congress

    Proof-of-Principle Quantitative EEG Study of CX-8998, an Oral, Potent and Selective T-Type Calcium antagonist in development for symptomatic treatment of Essential Tremor and Parkinson’s disease Tremor

    S. Papapetropoulos, M. Lee, S. Boyer (Cambridge, MA, USA)

    Objective: To study the pharmacodynamics (PD) of CX-8998, using pharmaco-electroencephalography (phEEG) and define plasma concentrations of CX-8998 which are pharmacologically active on objective CNS parameters.…
  • 2018 International Congress

    Analysis of secondary causes in Fahr’s syndrome and whole exome sequencing in Fahr disease from Northeast China and South Korean

    G. Shen, B. Jeon, G. Nan, S. Park (Changchun, China)

    Objective: In this study, patients with Fahr syndrome were analyzed for etiology, and genetic testing was performed for patients with Fahr disease from Northeast China…
  • 2018 International Congress

    Reduction of neuroinflammation by selective inhibition of the N-type calcium channel is beneficial in various animal models of neurodegeneration, here in the SOD1G93A transgenic mouse model of ALS

    J. Post-Schulz, A. Willuweit, V. Kogel, K. Langen, J. Kutzsche, D. Willbold (Jülich, Germany)

    Objective: Neuroinflammation is a pathological hallmark of several neurodegenerative diseases. We speculated that reduction of calcium ion influx specifically in neurons should reduce inflammatory cellular…
  • 2018 International Congress

    Pharmacological investigation of biochemical and behavioral effects resembling Huntington’s disease utilizing selective calcium and calmodulin dependent phosphodiesterase inhibitor

    R. Mishra (Baddi, India)

    Objective: To investigate the effects of selective phosphodiestrase (PDE) inhibitors in Nimodipine induced neuro degeneration (animal models of Huntington’s disease) in rats. Background: Nimodipine is…
  • 2018 International Congress

    Bone health and laboratorial correlations of Vitamin D in Parkinson’s disease

    L. Leandro, C. Moreira, H. Teive (Curitiba, Brazil)

    Objective: To evaluate the correlation between levels of 25 (OH)D (Vitamin D) and Bone Mineral Density (BMD) in a parkinsonian population. Background: Considering a limiting…
  • 2018 International Congress

    Spatiotemporal patterns of direct and indirect pathway striatal projection neurons in mouse model of Parkinson’s disease and dyskinesia

    C. Alcacer, M. Mendonca, A. Klaus, MA. Cenci, R. Costa (Lisbon, Portugal)

    Objective: To identify patterns of striatal projection neurons (SPN) activities that code for akinetic and dyskinetic movement disorders in a mouse model of hemiparkinsonism and…
  • 2017 International Congress

    Ataxia and increased cerebrospinal fluid phosphate associated with a mutation in the SLC20A2 gene

    M. Paucar, H. Almqvist, V. Jelic, G. Hagman, G. Jörneskog, S. Holmin, I. Björkhem, P. Svenningsson (Stockholm, Sweden)

    Objective: To characterize the phenotype and biochemical abnormalities associated with the R467X mutation in the SLCA20A2 gene. Background: Mutations in the SLC20A2 gene are the…
  • 2017 International Congress

    Efficient control of dopamine neuron physiology for rescuing disease phenotypes

    T. Rumbell, J. Kozloski (Yorktown Heights, NY, USA)

    Objective: Dopamine neurons (DAs) of the substantia nigra degenerate in Parkinson's disease and are disrupted in Huntington's disease. Here we propose single cell computational modeling…
  • 2017 International Congress

    Familial idiopathic basal ganglia calcification with novel SLC20A2 gene variant

    B. Barton (Chicago, IL, USA)

    Objective: Describe a family with brain calcifications related to new pathogenic variant of SLC20A2 gene. Background: Three genes are associated with the rare occurrence of autosomal…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley